Azathioprine in organ transplantation

Overview

Kidney, liver, heart, and lung transplantation represent some of medicine's most consequential achievements—and among its most pharmacologically demanding. The recipient's immune system recognises donor antigens as foreign and launches a rejection response unless that response is continuously suppressed. Without adequate immunosuppression, both acute and chronic rejection are inevitable. Azathioprine has been used as a core component of post-transplant therapy since the early 1960s, when Dr. Joseph Murray performed the first successful kidney transplant using AZA alongside corticosteroids.

Contemporary transplant protocols typically employ a three-drug combination: a calcineurin inhibitor (tacrolimus or cyclosporine), an antimetabolite (mycophenolate mofetil or azathioprine), and a corticosteroid (prednisolone). In many centres AZA retains a valued role as the antimetabolite of choice when MMF is not tolerated or is contraindicated—for example, in patients planning pregnancy or those with severe MMF-related gastrointestinal toxicity.

Rejection prophylaxis

Transplant rejection is classified by timing: hyperacute rejection (minutes to hours post-transplant, mediated by pre-formed antibodies); acute rejection (days to months, predominantly T-cell-mediated); and chronic rejection (months to years, involving both cellular and humoral mechanisms). Azathioprine, by inhibiting lymphocyte proliferation, primarily counteracts acute T-cell-mediated rejection and contributes to chronic rejection prevention as part of maintenance regimens.

In the transplant setting, AZA is typically dosed at 1–2 mg/kg/day. The dose should be titrated to the CBC response: a white cell count falling below 3,500/mm³ is a signal to reduce or temporarily hold the dose. Dose changes and discontinuation must always be coordinated with the transplant team; abrupt cessation can precipitate acute rejection.

Combination therapy

The standard triple-therapy regimen (calcineurin inhibitor + antimetabolite + corticosteroid) underpins most transplant protocols. Tacrolimus has largely replaced cyclosporine as the preferred calcineurin inhibitor, with lower acute rejection rates in most studies. MMF demonstrates some advantages over AZA in reducing acute rejection, but AZA remains a valuable alternative when MMF is not tolerated or when a patient is planning pregnancy (MMF is teratogenic; AZA is classified as relatively safer in pregnancy under transplant team guidance).

Drug interactions are critically important in transplant patients. Fluoroquinolone antibiotics and azole antifungals (fluconazole, voriconazole) raise tacrolimus and cyclosporine levels significantly. Enzyme inducers such as rifampicin, phenytoin, phenobarbital, and some antiretrovirals lower calcineurin inhibitor levels and can precipitate rejection. Every new medication—including supplements, herbal products, and over-the-counter drugs—must be cleared with the transplant pharmacist or physician. Grapefruit and grapefruit juice must be avoided, as they inhibit intestinal CYP3A4 and raise calcineurin inhibitor levels unpredictably.

Monitoring

Structured surveillance is a lifelong requirement after transplantation. Routine panels include: complete blood count (to detect AZA-related myelosuppression), serum creatinine and urinalysis (allograft function), liver enzymes (AST, ALT), tacrolimus or cyclosporine trough levels, fasting glucose (post-transplant diabetes mellitus risk), and a fasting lipid panel. Monitoring frequency is highest in the first weeks post-transplant and is tapered as the patient stabilises—but it never stops.

Symptoms requiring urgent reporting include: any fever or rigours (even low-grade), reduced or discoloured urine output, pain or swelling over the transplant site, sudden blood pressure changes, jaundice, unexplained fatigue, or any unusual symptoms. Opportunistic infections (CMV, BK virus, invasive fungal disease) are far more dangerous in transplant recipients than in immunocompetent individuals; early identification and treatment are essential.

Lifestyle

Vaccination is an integral part of post-transplant care. All inactivated vaccines (influenza, pneumococcal, hepatitis B, tetanus) should be kept up to date per transplant team scheduling. Live attenuated vaccines (MMR, varicella, live yellow fever) are generally contraindicated under systemic immunosuppression unless explicitly approved by the transplant physician. Close household contacts should also maintain current vaccinations to protect the recipient through herd immunity.

A heart-healthy diet (low sodium, low saturated fat, rich in vegetables and fruit), maintenance of a healthy weight, and regular physical activity as guided by the team all improve long-term outcomes. Sun protection is particularly important: the risk of squamous cell carcinoma of the skin is substantially elevated in long-term immunosuppressed patients. Broad-spectrum high-SPF sunscreen, protective clothing, and regular dermatological review are recommended. Tobacco and alcohol must be avoided. Exposure to individuals with active respiratory or other infections should be minimised.

Summary

Azathioprine continues to play a role in transplant maintenance regimens, particularly for patients who cannot tolerate MMF. Long-term transplant success depends on strict medication adherence, regular laboratory monitoring, awareness of drug interactions, attention to lifestyle factors, and sustained engagement with the transplant team. An informed, active patient who communicates openly with their care team achieves the best long-term transplant outcomes.